CIK 0001817229 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Net income (USD) | -696.0 M | -117.9 M | -92.1 M |
| Diluted EPS (USD/shares) | -70.5 | -1.75 | -2.33 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-05 | 4 | 4 | 2026-10-02 |
| 2026-09-04 | S-3ASR | S-3ASR | |
| 2026-08-26 | 4 | 4 | 2026-08-24 |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-13 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-11 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-07 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-06 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-07-30 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-07-21 | SCHEDULE 13D/A | SCHEDULE 13D/A | |
| 2026-07-21 | 4 | 4 | 2026-07-16 |
| 2026-07-09 | 3 | 3 | 2026-07-07 |
| 2026-07-09 | 4 | 4 | 2026-07-07 |
| 2026-07-07 | 8-K | 8-K items 5.02,9.01 | 2026-07-06 |
| 2026-06-12 | 4 | 4 | 2026-06-11 |
| 2026-06-12 | 4 | 4 | 2026-06-11 |
| 2026-06-12 | 4 | 4 | 2026-06-11 |
| 2026-06-12 | 4 | 4 | 2026-06-11 |
| 2026-06-12 | 4 | 4 | 2026-06-11 |
| 2026-06-12 | 4 | 4 | 2026-06-11 |
| 2026-06-12 | 4 | 4 | 2026-06-11 |
| 2026-06-12 | 4 | 4 | 2026-06-11 |
| 2026-06-12 | 8-K | 8-K items 5.07,9.01 | 2026-06-11 |
| 2026-06-08 | 8-K | 8-K items 7.01,9.01 | 2026-06-08 |
Forms on file (last 1,000): 4 179, 8-K 48, 3 32, SCHEDULE 13D/A 24, 144 22, SCHEDULE 13G/A 17, 10-Q 17, SCHEDULE 13G 11. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=VOR (0.002 USD), /gw/filings/filings?ticker=VOR&form=8-K, /gw/filings/facts?ticker=VOR&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange